Furthermore, there are profound differences in T2DM pathophysiology in Asians and Westerns [21], and the FPG targets for basal insulin therapy in Caucasian patients may well not be appropriate for Asians. The gene discussed is INS; the disease is type 2 diabetes mellitus.